Table 2.
Table 2 shows the pCR rates according to LAR and non-LAR groups for 13 neoadjuvant chemotherapy (NAC) treatment arms across seven clinical trials. Within the LAR group, the pCR response rates ranged from 13.3% to 45.5%, while within the non-LAR group, the pCR rates ranged from 35.6% to 71.7%. The sample size within the LAR group was small for many of the NAC treatment arms; however, in 11 of the 13 NAC treatment arms, the pCR rate was higher in the non-LAR group than in the LAR group. We performed a meta-analysis to summarize the LAR effect across the 13 NAC treatment arms, as measured by the odds ratio [non-LAR vs LAR]. A random-effects logit model was adopted [1]. In the model, the NAC treatment arm effects were treated as random as opposed to fixed to better capture the variability inherent in the system more realistically; furthermore, the model included random LAR effects such that the LAR effect was not constrained to be identical in each trial arm stratum. The odds ratio's expected or average value [95% CI] was 2.11 [1.33, 2.89]. There was strong evidence of a LAR effect such that within the non-LAR group, the odds of achieving a pCR was 2.11 times the odds within the LAR group
| pCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Id | Trial | NAC Treatment | Arm | Group | Yes | No | Total | % Yes | Odds Ratio |
| A | GSE106977 | Taxane + AC | A | LAR | 2 | 13 | 15 | 13.33% | 5.68 |
| non-LAR | 34 | 39 | 73 | 46.58% | |||||
| Taxane + Carboplatin+A/C | B | LAR | 1 | 6 | 7 | 14.29% | 3.60 | ||
| non-LAR | 9 | 15 | 24 | 37.50% | |||||
| B | GSE25055 | Taxane + AC | - | LAR | 4 | 17 | 21 | 19.05% | 2.45 |
| non-LAR | 34 | 59 | 93 | 36.56% | |||||
| C | GSE25065 | Taxane + AC | - | LAR | 1 | 8 | 9 | 11.11% | 2.52 |
| non-LAR | 18 | 27 | 45 | 40.00% | |||||
| D | GSE32646 | Taxane + FEC | - | LAR | 2 | 4 | 6 | 33.33% | 1.33 |
| non-LAR | 8 | 12 | 20 | 40.00% | |||||
| E | BrightNess | Taxane + Veliparib + Carboplatin+A/C | A | LAR | 15 | 25 | 40 | 37.50% | 2.20 |
| non-LAR | 112 | 85 | 197 | 56.85% | |||||
| BrightNess | Taxane + Carboplatin + A/C | B | LAR | 10 | 12 | 22 | 45.45% | 1.73 | |
| non-LAR | 59 | 41 | 100 | 59.00% | |||||
| BrightNess | Taxane + AC | C | LAR | 4 | 18 | 22 | 18.18% | 2.49 | |
| non-LAR | 36 | 65 | 101 | 35.64% | |||||
| F | CALGB 40603 | Taxane + AC | 1 | LAR | 6 | 6 | 12 | 50.00% | 0.63 |
| non-LAR | 20 | 32 | 52 | 38.46% | |||||
| CALGB 40603 | Taxane + Bevacizumab + A/C | 2 | LAR | 5 | 8 | 13 | 38.46% | 1.52 | |
| non-LAR | 20 | 21 | 41 | 48.78% | |||||
| CALGB 40603 | Taxane + Carboplatin + A/C | 3 | LAR | 6 | 6 | 12 | 50.00% | 1.00 | |
| non-LAR | 23 | 23 | 46 | 50.00% | |||||
| CALGB 40603 | Taxane + Carboplatin + Bevacizumab + A/C | 4 | LAR | 5 | 7 | 12 | 41.67% | 3.55 | |
| non-LAR | 38 | 15 | 53 | 71.70% | |||||
| G | Beauty | Taxane + AC | - | LAR | 2 | 7 | 9 | 22.22% | 6.13 |
| non-LAR | 21 | 12 | 33 | 63.64% | |||||